In this research, we showed that injection of Tat‐SIRT5‐CTM led to effective transport of the peptide into brain tissue and that administration of the peptide within 6 h of stroke produced a therapeutic effect; this is in contrast to the therapeutic time window of tPA, which is < 4.5 h after stroke onset.44 The gene discussed is TAT; the disease is stroke disorder.